Clinical Trial Search

Primary: Percentage of Patient-visits Prescribed an Antimicrobial at Their ED Visit — 21.2; 20.9; 19.1; 21.6 percentage of visits prescribed an abx — p=0.35

Primary: Depression (PHQ-9 Instrument) — 6.48; 5.84; 3.44 score on a scale

Primary: Period 1: Percent Absolute Bioavailability (%F) for TAK-831 — 17.34 percent absolute bioavailability

Primary: Degree of Lesion Contrast Enhancement — 0.884; 0.863; 3.007; 2.979 Scores on a scale — p=< 0.0001

Primary: Change in HbA1c From Baseline at Week 24 — -0.51; -0.10 % of HbA1c — p=0.0012

Primary: Number of Participants With Adverse Events — 18; 21; 21 Participants

Primary: Number of Participants Attending More Than 50% of Intervention Sessions and Number of Participants Reporting Satisfaction With the Intervention Sessions — 118; 63; 58…

Primary: Number of Participants With Serious Adverse Events (SAEs) — 0; 1; 1; 1 Participants

Primary: Number of Participants Who Self-report Prolonged Abstinence From Smoking — 3; 0 Participants

Primary: Maximum Observed Plasma Concentration (Cmax) of GDC-9545 — 126; 129; 102 nanograms per millilitre (ng/mL)

Primary: Percentage of Participants Diagnosed With Acromegaly — 5.8; 2.4 percentage of participants

Primary: Rate of Hypotension, Serious Adverse Events, GI Events and Cardiovascular Death — 1; 6; 5; 3 Participants — p=0.04

Primary: Sensitivity of Endoscopic Ultrasound-guided (EUS-guided) Puncture — 93 percentage

Primary: Number Adverse Events (AEs) — 7; 2; 1; 9 adverse events

Primary: Change From Baseline in HbA1c at 24 Weeks — -0.59; -0.31 percentage of glycated hemoglobin — p=0.0026